

Supplementary Table 1 Previous antibiotic therapies of the enrolled patients and its eradication rates

Previous regimen	500mg b.i.d.	750mg b.i.d.	500mg t.i.d.	N
Amoxicillin +Furazolidone	83.3% (5/6)	88.2% (15/17)	83.3% (10/12)	35
Amoxicillin + clarithromycin	0	0 (0/2)	100% (/2)	4
Rifaximin + clarithromycin	50% (1/2)	0	100% (1/1)	3
Levofloxacin + Clarithromycin	100% (1/1)	100% (2/2)	0	3
Furazolidone +Clarithromycin	100% (1/1)	100% (4/4)	100% (3/3)	8
Amoxicillin + Doxycycline	100% (1/1)	0	0	1
Levofloxacin + Furazolidone	0	100% (2/2)	0	2
Levofloxacin + Rifaximin	0	0	100% (1/1)	1
Tetracycline + Furazolidone	0	100% (/2)	100% (1/1)	3
unknown	85.7% (6/7)	84.6% (11/13)	100% (5/5)	25

500mg b.i.d.: tetracycline twice daily;750mg b.i.d.: tetracycline twice daily;
500mg t.i.d.: tetracycline three times daily.

Supplementary Table 2 Demographic and clinical data of patients

Group	500mg b.i.d.	750mg b.i.d.	500mg t.i.d.	P value
N	157	118	119	
Age (mean, SD)	47.9±13.6	45.5±13.8	45.1±14.4	0.175
Gender (M/F)	55/102	44/74	38/81	0.685
Smoking	17	12	7	0.331
Alcohol drinking	28	16	25	0.317
Education				0.099
Primary school	29	19	19	
High school	65	40	44	
College	56	57	56	
Endoscopy diagnosis				0.05
Gastritis	112	86	71	
Gastric ulcer	5	1	1	
Duodenal ulcer	16	6	16	
Complex ulcer	0	1	1	
unknown	24	24	30	
Intestinal metaplasia	78	63	52	0.109
Treatment line ^a				0.003
First therapy	136	79	94	
Rescue therapy	18	32	22	
≥3	3	7	3	
Type 2 diabetes	11	6	6	0.723
Hypertension	25	15	23	0.359
Hyperlipidemia	11	7	9	0.88
Penicillin allergy	24	22	30	0.115

M, male; F, female; 500mg b.i.d., tetracycline twice daily; 750mg b.i.d., tetracycline twice daily; 500mg t.i.d., tetracycline three times daily.

a: recording this treatment as start of frequency. Rescue therapy was defined

as patients who had eradicated therapy once or more but failed.

Supplementary Table 3. Analysis of Eradication Rates by Treatment line Subgroups in Penicillin Allergic Patients

Treatment line	500mg b.i.d.	750mg b.i.d.	500mg t.i.d.
1	95.0% (19/20)	100% (15/15)	89.3% (25/28)
2	75.0% (3/4)	92.7% (5/6)	100% (2/2)

500mg b.i.d.: tetracycline twice daily;750mg b.i.d.: tetracycline twice daily;
500mg t.i.d.: tetracycline three times daily.

Supplementary Table 4. Univariate analysis and multivariable analysis of the predictive factors for H. pylori eradication failure

Variable	Univariate analysis		Multivariate analysis	
	OR (95%CI)	<i>P</i> value	Adjusted OR(95%CI)	<i>P</i> value
Age				
≤50	1[Reference]	NA	1[Reference]	NA
>50	1.821 (0.841-3.943)	0.128	0.502 (0.149-1.692)	0.267
Gender				
female	1[Reference]	NA	1[Reference]	NA
Male	2.314 (0.998-4.564)	0.051	1.241 (0.429-3.594)	0.690
Education				
Primary school	1[Reference]	NA	1[Reference]	NA
Middle school	0.810 (0.287-2.291)	0.692	1.216 (0.352-4.194)	0.757
College	0.708 (0.251-1.998)	0.514	1.235 (0.298-5.126)	0.771
Smoking				
No	1[Reference]	NA	1[Reference]	NA
Yes	2.245 (0.800-6.296)	0.124	0.981 (0.212-4.528)	0.980
Alcohol drinking				
No	1[Reference]	NA	1[Reference]	NA
Yes	1.899 (0.804-4.484)	0.144	1.126 (0.305-4.151)	0.859
Treatment Line				
First line	1[Reference]	NA	1[Reference]	NA
Rescue therapy	2.403 (1.088-5.307)	0.030	2.530 (0.910-7.037)	0.075
Type 2 diabetes				
No	1[Reference]	NA	1[Reference]	NA
Yes	4.016 (1.373-11.752)	0.011	2.545 (0.640-10.125)	0.185
Hypertension				
No	1[Reference]	NA	1[Reference]	NA

Yes	6.964 (3.163-15.333)	<0.001	7.885 (2.582-24.081)	<0.001
Hyperlipidemia				
No	1[Reference]	NA	1[Reference]	NA
Yes	6.937 (2.720-17.691)	0	3.697 (1.149-11.899)	0.028
Intestinal metaplasia				
Yes	1[Reference]	NA		
No	1.559 (0.627-3.879)	0.339		
Family history				
No	1[Reference]	NA		
Yes	1.728 (0.376-7.954)	0.482		
Endoscopy diagnosis				
		0.751		
Gastritis				
Gastritis	1[Reference]	NA		
Ulcer	0.499 (0.113-2.196)	0.358		
PPI		0.882		0.570
Pantoprazole	1[Reference]	NA	1[Reference]	NA
Esomeprazole	0.625 (0.199-1.969)	0.422	0.486 (0.127-1.867)	0.294
Rabeprazole	0.854 (0.375-1.943)	0.706	0.504 (0.174-1.463)	0.207
Lansoprazole	/	0.999	/	0.999
Bismuth				
Bismuth	1[Reference]	NA	1[Reference]	NA
potassium citrate				
Colloidal	1.525 (0.625-3.725)	0.354	1.057 (0.340-3.290)	0.923
bismuth pectin				
Regimen and dose		0.959		
500mg b.i.d.	1.011 (0.412-2.486)	0.98	0.971 (0.327-2.884)	0.957

750mg b.i.d.	0.889 (0.331-2.388)	0.815	1.039 (0.304-3.550)	0.952
500mg t.i.d.	1[Reference]	NA	1[Reference]	NA

NA: not applicable; HR: hazard ratio; 500mg b.i.d.: tetracycline twice daily; 750mg b.i.d.: tetracycline twice daily; 500mg t.i.d.: tetracycline three times daily. Adjusted for age, gender, education, smoking, alcohol drinking, hypertension, hyperlipidemia, diabetes, treatment line, bismuth type, PPI type and treatment regimen.